Lifesci Capital Has Bullish Estimate for CRNX Q2 Earnings

Key Points

• Lifesci Capital raised its Q2 2026 EPS estimate for Crinetics Pharmaceuticals to a loss of $1.22 per share from $1.34 and kept a Strong-Buy rating on the stock.
• The firm also lifted its estimates for Q3, Q4, and full-year 2026, signaling a more optimistic near-term outlook even though Crinetics is still expected to post a sizable annual loss.
• Crinetics recently reported Q1 EPS of -$1.23, narrowly missing estimates, while revenue came in above expectations at $10.73 million; the stock was trading around $36.55 and remains well below the average analyst price target of $76.13.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) - Equities researchers at Lifesci Capital upped their Q2 2026 earnings per share (EPS) estimates for shares of Crinetics Pharmaceuticals in a research note issued to investors on Friday, May 8th. Lifesci Capital analyst K. Dellorusso now forecasts that the company will post earnings of ($1.22) per share for the quarter, up from their previous forecast of ($1.34). Lifesci Capital currently has a "Strong-Buy" rating on the stock. The consensus estimate for Crinetics Pharmaceuticals' current full-year earnings is ($4.95) per share. Lifesci Capital also issued estimates for Crinetics Pharmaceuticals' Q3 2026 earnings at ($1.18) EPS, Q4 2026 earnings at ($1.10) EPS and FY2026 earnings at ($4.73) EPS.

CRNX has been the topic of several other research reports. The Goldman Sachs Group upgraded Crinetics Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $67.00 price target on the stock in a report on Monday, January 12th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Crinetics Pharmaceuticals in a report on Monday, April 20th. Oppenheimer reduced their price target on Crinetics Pharmaceuticals from $87.00 to $84.00 and set an "outperform" rating on the stock in a report on Monday. Citizens Jmp reduced their price target on Crinetics Pharmaceuticals from $97.00 to $95.00 and set a "market outperform" rating on the stock in a report on Friday. Finally, Wall Street Zen lowered Crinetics Pharmaceuticals from a "sell" rating to a "strong sell" rating in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $76.13.

Crinetics Pharmaceuticals Stock Down 2.5%

NASDAQ CRNX opened at $36.55 on Tuesday. Crinetics Pharmaceuticals has a 52 week low of $25.83 and a 52 week high of $57.99. The business's fifty day simple moving average is $38.14 and its 200-day simple moving average is $43.81. The firm has a market cap of $3.85 billion, a PE ratio of -7.12 and a beta of 0.28.

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.23) EPS for the quarter, missing the consensus estimate of ($1.22) by ($0.01). Crinetics Pharmaceuticals had a negative return on equity of 43.96% and a negative net margin of 2,747.18%.The company had revenue of $10.73 million for the quarter, compared to analysts' expectations of $8.51 million. During the same quarter in the prior year, the firm earned ($1.04) EPS. The firm's revenue was up 2873.4% on a year-over-year basis.

Insider Transactions at Crinetics Pharmaceuticals

In related news, insider Jeff E. Knight sold 85,163 shares of the business's stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $40.10, for a total value of $3,415,036.30. Following the sale, the insider directly owned 105,289 shares in the company, valued at approximately $4,222,088.90. The trade was a 44.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Stephen F. Betz sold 10,612 shares of the business's stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $37.37, for a total transaction of $396,570.44. Following the completion of the sale, the insider owned 137,101 shares in the company, valued at approximately $5,123,464.37. This trade represents a 7.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 142,380 shares of company stock worth $5,569,475 in the last 90 days. Insiders own 3.80% of the company's stock.

Institutional Trading of Crinetics Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of CRNX. Smartleaf Asset Management LLC increased its stake in Crinetics Pharmaceuticals by 107.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 639 shares of the company's stock worth $30,000 after purchasing an additional 331 shares during the period. Headlands Technologies LLC purchased a new stake in Crinetics Pharmaceuticals during the second quarter worth about $30,000. Farther Finance Advisors LLC increased its stake in Crinetics Pharmaceuticals by 523.7% during the third quarter. Farther Finance Advisors LLC now owns 842 shares of the company's stock worth $35,000 after purchasing an additional 707 shares during the period. Raymond James Financial Inc. purchased a new stake in Crinetics Pharmaceuticals during the second quarter worth about $45,000. Finally, Parallel Advisors LLC increased its stake in Crinetics Pharmaceuticals by 34.6% during the fourth quarter. Parallel Advisors LLC now owns 1,225 shares of the company's stock worth $57,000 after purchasing an additional 315 shares during the period. 98.51% of the stock is currently owned by hedge funds and other institutional investors.

Crinetics Pharmaceuticals News Roundup

Here are the key news stories impacting Crinetics Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital raised its Q2, Q3, and Q4 2026 EPS estimates for Crinetics Pharmaceuticals and kept a Strong-Buy rating, signaling improved near-term expectations. The firm also lifted its FY2026 EPS estimate from a larger loss to a somewhat smaller loss.
• Positive Sentiment: A Yahoo Finance-linked note said analysts are lifting estimates after Crinetics reported first-quarter earnings, suggesting the recent quarter may have reassured some investors about the company’s execution. Crinetics Pharmaceuticals, Inc. NASDAQ: CRNX Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
• Neutral Sentiment: Oppenheimer cut its price target on Crinetics Pharmaceuticals to $84 from $87, but maintained an Outperform rating. This is still above the current trading level, yet the cut can weigh on sentiment. Crinetics Pharmaceuticals NASDAQ: CRNX Price Target Cut to $84.00 by Analysts at Oppenheimer
• Neutral Sentiment: HC Wainwright trimmed multiple longer-term EPS estimates, including FY2026, FY2027, FY2028, and FY2029, reflecting a more conservative outlook beyond the next few quarters.
• Neutral Sentiment: Crinetics remains a loss-making biotech, with consensus FY2026 EPS still expected at a loss of $4.95 per share, so the stock is highly sensitive to changes in development and profitability expectations.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company's proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics' research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company's lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.